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ALESSI, N. E., P. QUINLAN AND H KHACHATURIAN. MSG effects on beta-endorphm and alpha-MSH m the 
hypothalamus and caudal medulla PEPTIDES 9(4) 689-695, 1988.--Monosodmm glutamate (MSG) was given to neonatal 
male rats to determine its effects on neurons contmnlng beta-endorphm (B-END) and alpha-melanocyte stimulating hor- 
mone (a-MSH) within the basal hypothalamus (arcuate nucleus) and caudal medulla [nucleus tractus sohtarlus (NTS)I and 
on the levels of B-END and c~-MSH within these areas. Immunocytochemlcal studies demonstrated a reduction in the 
number of cells within the medial hypotbalamlc area (arcuate nucleus) among MSG-treated ammals versus saline controls. 
MSG did not reduce the number of cell bodies within the caudal medulla (NTS). MSG slgmficantly reduced B-END and 
a-MSH lmmunoreactive levels m the basal hypothalamus as determined by radmlmmunoassay. Whereas a slgmficant 
reduction in the level of B-END occurred in the ventral caudal medulla (VCM), none occurred in the dorsal caudal medulla 
(DCM) In contrast, levels of a-MSH increased slgmficantly m the DCM among animals receiving MSG compared to 
control animals. This study documents the contribution of beta-endorphm contmnmg neurons of the basal hypothalamus to 
areas of the caudal medulla. The effect of MSG on beta-endorphln and a-MSH neurons in these areas and their differentml 
effects on levels in the caudal medulla areas raises questmns about the sites of ongm of these pept~des. 
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PERIKARYA containing pro-opiomelanocortm (POMC) 
and its products, e.g., beta-endorphin (B-END) and alpha- 
MSH (a-MSH), are found in the arcuate nucleus and 
nucleus tractus solitarius (NTS) within the central nervous 
system [1, 9, 11]. B-END immunoreactive fibers are found in 
dorsal and ventral caudal medulla. Although the origin of 
these fibers is unknown, retrograde track tracing has 
demonstrated that cell bodies in the hypothalamus project to 
the NTS [19]. Radmimmunoassay studies in the adult rat, 
utihzlng either the entire caudal medulla or dorsal caudal 
medulla, indicate that the major POMC products are a-MSH 
and B-END [1, 2, 4]. Given the potential physiological ac- 
tions of either a-MSH or B-END, it is important to discern 
not only their quantity but where these peptides may origi- 
nate, i.e., the basal hypothalamus or the caudal medulla. 
In the following study, monosodium glutamate (MSG) 
was administered to rats to assess the effects of MSG treat- 
ment on B-END and a-MSH in the caudal medulla and the 
basal hypothalamus. The administration of MSG during de- 
velopment has been demonstrated to result in loss of 
perikarya in the medial basal hypothalamus (arcuate nu- 
cleus) and a reduction in the B-END and a-MSH am- 
munoreactivity m the brain [5,13]. The combinatmn of these 
approaches, radioimmunoassay and immunocytochemistry, 
were utihzed to discern the relationship of the visable reduc- 
tion in the number of perikarya with reduced levels of 
B-END and a-MSH. 
METHOD 
Monosodtum Glutamate Treatment (MSG) 
Monosodium glutamate (MSG) was administered intra- 
peritoneally to cross-fostered male Sprague-Dawley rats at 
postnatal days 2, 4, 6 and 8. The dosage was 4 mg per gram 
body weight in a delivery volume of 100 microliters [14,15]. 
The control httermates received 100 macroliters of 10% 
saline intraperitoneally at the same ages. Eaghteen (40%) of 
forty-five MSG-treated animals survived to adulthood with 
the highest death rate occurring between postnatal days 6 
and 12. None of the control littermates died. Litters were 
housed in a twelve hour light-dark cycle (light from 0600 to 
1800) with food and water provided ad lib. At postnatal day 
21, the MSG and control rats were weaned and placed m 
maxed groups of six per cage. 
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The rats were housed in groups of up to six per cage until 
the ages of 95 and 105 days at which time they were killed by 
decapitation Six MSG and saline animals were randomly 
selected from these groups and served as the basis for the 
radiolmmunoassay studies. Following decapitation the 
brains were removed from the skull and regions were dis- 
sected immediately [6]. Upon dissection, the ports-medulla 
tissue block was frozen on dry Ice. The caudal medulla was 
dissected using the obex as the anterior boundary and the 
medulla-cord junction as the posterior boundary. The caudal 
medulla was then separated into ventral and dorsal regions 
using the central canal as the plane ot division The collected 
nssue was stored at -80°C Tissue extraction was performed 
as previously described [2]. The regions selected for study 
consisted of the hypothalamus, ventral medulla (VCM), and 
dorsal caudal medulla (DCM) 
Radtolmmunoa~say oJ Beta-Endorphm and Alpha-MSH 
The/3-END radlolmmunoassay (R1A) procedure was per- 
formed as previously described [3]. The assay consisted of a 
three-day dlsequlhbnum procedure using 4% sheep ann- 
rabbit globulin serum as the second antibody. The peptlde 
used as the standard and for lodlnatlon was human/3-END 
1-31 (Cat. No. 8616, Peninsula Lab, Belmont, CA) The 
antiserum was donated by Dr. Huda Akll (Mental Health 
Research Institute, University of Michigan). The IC~., for the 
assay was 8.58_+0.65 femtomoles/tube and the sensitivity 
was 2.63_+0 35 femtomoles/tube The lnterassay coefficient 
of variation was 7.52% and the lntraassay coefficient of var- 
Iation was 6 8%. 
The B-END antiserum is 100% crossreactlve with its 
larger molecular weight precursors, POMC or beta- 
hpotropln The antiserum showed no cross reactlwty with 
gamma-endorphln (/3-END 1-16), ACTH, c~-MSH, 
gamma-MSH, [Leu] or [Met] enkephahn, dynorphln related 
peptldes or a number of nonoplo~d pitmtary pepndes A 
complete characterization of the antiserum can be found m 
Cahill et al. [3] The/3-END lmmunoreactivlty measured in 
the RIA was the sum total of/3-END, beta-hpotropln, and 
POMC lmmunoreactlvltles 
The ~-MSH assay procedure was performed as previ- 
ously described [2] The assay consisted of a five-day dls- 
equlhbnum procedure using 5% sheep anti-rabbit globulin 
serum as the second antibody. The peptlde used as the 
standard and for iodinatlon was c~-MSH (Cat No 7251, 
Peninsula Laboratories, Belmont, CA). The antlsera 
(Number 24) was donated by Dr. Thomas O'Donohue (form- 
erly of Monsanto) The final dilution for antlsera was 
1/30,000 The IC~ for the assay was 14.86_+0.61 femtomoles/ 
tube and the sensitivity was 4 0_+0.30 femtomoles/tube, The 
interassay coefficient of variation was 15 3% The c~-MSH 
antisera is 100% crossreactlve with c~-MSH, des-acetyl 
~-MSH, and deaminated c~-MSH. The antiserum was 0 0% 
crossreactive with ACTH 1-24, human ACTH 1-39, human 
/3-END 61-91, human beta-llpotrophin and ACTH 1-10, 
ACTH 4-10 or ACTH 4-11 Protein levels were determined 
utilizing a standard procedure [12]. The Student 's t-test 
for unpaired samples was used to assess the levels of signifi- 
cance between sample means 
Colchlcme Pretreatment 
To enhance the visualization of neuronal perikarya col- 
chlclne (250/~g in 10/zl 0 ~ saline) was injected intracere- 
broventrlcularly into adult rats, MSG- or sahne-pretreated, 
from which brains were taken for ~mmunocytochemlstry. 
Only animals whose brains were used for lmmunocytochem- 
istry were given colchlcine prior to sacnfice The main ac- 
tion of colchlclne is inhibition of mlcrotubule synthesis, re- 
suiting in retardation of axonal transport and an accumula- 
tion of synthesized material m neuronal perlkarya [7] For 
inJection, each animal was anesthetized with sodmm pen- 
tobarbltal (5-10 mg per animal), the skull exposed, and col- 
chlcine inJected into the right lateral ventricle. The skull 
opening was filled in with bone wax and the scalp closed 
using wound clips. Animals were allowed to recover for 48 
hours, and then sacrificed as described below. 
lmrnuno¢ ytochemt strv oJ Beta-Endorphm 
Brain sections were prepared for lmmunocytochemlstry 
as described previously [10] Rats were anesthetized with 
sodium pentobarbltal (50 mg/kg) given lntraperltoneally and 
placed on crushed ice. The cardiovascular system was 
flushed with 0 9% sahne followed by perfuslon with ice-cold 
4% formaldehyde (pH 7.4) In 0 1 M phosphate buffer, for 30 
minutes. The brains were removed promptly and placed in 
the same fixanve for an additional hour, after which they 
were transferred into 15% sucrose in phosphate-buffered 
saline (PBS) and refrigerated overnight. Tissue blocks were 
frozen onto brass cryostat chucks with liquid nitrogen and 
sectioned in a cryostat at -20°C. Sections of 20/~m thickness 
were thaw-mounted onto gelatin-coated slides and stored at 
- 80oc. 
Primary rabbit antiserum to/3-END (gift of Dr. Stanley 
Watson, Mental Health Research Institute, University of 
Michigan) was diluted with 0.3% Triton X-100 in 0 02 M 
PBS, added onto the sections, and allowed first to incubate 
for 1 hour at 37°C, then overnight at 4°C After 3× 10 minutes 
PBS washes, the sections were incubated with goat anti- 
rabbit serum (Arnel) for 30 minutes at 37°C and then at 4°C 
overmght. The sections were again washed In PBS, and in- 
cubated m successive steps with horseradish peroxldase 
(HRP) antiserum, followed by another PBS wash, and HRP 
enzyme (Sigma, Type VI) for 40 minutes, each at 37°C The 
slides were then washed in PBS and immersed in a solution 
of 0.03% hydrogen peroxide and 0 125 mg/ml dxamlnoben- 
Zldlne (Sigma) for 15 minutes with constant stirring. The 
sections were washed in d~stllled water, bnefly osmlcated 
(2% osmium tetroxlde), washed, dehydrated through 
ethanols and xylenes and mounted in Permount Observa- 
tions and photography were performed using a Leitz Ortho- 
plan Microscope 
RESULTS 
Figure 1 shows the total body weights (grams) and whole 
brain wet weights (milligrams) of MSG and saline groups of 
animals The total body weights (mean_+SEM) of the animals 
receiving MSG (340_ + 14 grams) were significantly lower 
(p<0.005) than animals receiving sahne (419_+17 grams) 
Brain wet weights were also significantly lower (p <0 005) in 
the MSG-treated animals (1,740_+50 milligrams) compared 
to control animals (2,090_+40 milligrams). The pattern of the 
reduced brain wet weight in MSG animals was noted for the 
DCM and VCM, as well (Fig. 2). The DCM showed a signifi- 
cant reduction (p <0.005), but a greater reduction was seen in 
the VCM with the values 29 25-+0.71 milligrams among 
saline control animals versus 19 38-+1 5 milligrams among 
the MSG animals (p<0 0001). There was no slgmficant 











































BODY WHOLE BRAIN 
FIG 1 Total body weight (grams) and whole brain wet weight (md- 
hgrams) m MSG versus control rats Unshaded bar represents sahne 
control ammals, shaded bar represents MSG ammals N=6 per 
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FIG 2 Wet weights (mdhgrams) of hypothalamus, dorsal caudal 
medulla, and ventral caudal medulla of MSG versus control rats 
Unshaded bar represents sahne control animals, shaded bar repre- 
sents MSG ammals N=6 per area per condmon mg=mdhgrams. 
difference in hypothalamus wet weights between saline con- 
trol (35.25+1.97 milligrams) and MSG- (30.13-+2.55 mdli- 
grams) treated animals. 
The lmmunocytochemical  study of B-END within the 
hypothalamus and caudal medulla of  saline control versus 
MSG rats as presented in Fig. 3. In Fig. 3A, the presence of 
B-END staining cell bodies is apparent in the arcuate nucleus 
of saline control animals. In Fig 3B, the reduction m cell 
number in the medial basal hypothalamus (arcuate nucleus) 
is prominent. Of note is the increase in size of perikarya 
contained within the lateral basal bypothalamlc area. In 
comparison, the number of cell bodies within the caudal 
medulla were not reduced among MSG-treated animals ver- 
sus saline control, nor did there appear to be an alteration in 
the size of the cell bodies, as was noted in the lateral hypo- 
thalamic B-END containing cells (Fig. 3C and D). 
The values (mean_+SEM) of  B-END immunoreactivlty 
in the animals receiving saline were 976.14_+3.637 
fmol/mg protein for hypothalamus. 86.20_+10.92 fmol/mg 
protein for the VCM, and 44.49-+4.51 fmol/mg protein for 
the DCM. The VCM had a significantly higher concentra- 
tion of  B-END immunoreactivity than the DCM 
(p<0.005).  Among the MSG-treated animals, B-END lm- 
munoreactivity significantly decreased in the hypothala- 
mus (p<0.0005) and the VCM (p<0.025)  to 371.50-+60 90 
fmol/mg protein and 37.73_+6.40 fmol/mg protein, respec- 
tlvely. B-END ~mmunoreactivaty In the DCM did not signifi- 
cantly decrease wath B-END lmmunoreachvity being 
36.34_+6.90 fmol/mg protein (see Fig. 4). 
The values (mean_+SEM) of c~-MSH-llke ammunoreactlve 
material in the animals receiving sahne were 229 28_+43.53 
fmol/mg protein for the hypothalamus, 29.51_+4.33 fmol/mg 
protean for the VCM, and 17.14_+ 1.24 fmol/mg protein for the 
DCM. The VCM had a slgmficantly higher concentration of 
c~-MSH than the DCM (p<0.025). In the MSG-treated 
animals, a-MSH slgmficantly decreased in the hypothalamus 
from 229.28_+43.53 to 85.31_+6.48 fmol/mg protein (p< 
0.005). Whereas c~-MSH m the DCM significantly in- 
creased (p<0.01) from 17.14_+1.24 to 28.28_+3.79 fmol/mg 
protein, levels within the VCM did not significantly change 
(p<N S.) (see Fig. 5). 
D I S C U S S I O N  
The administration of monosodium glutamate (MSG) dur- 
ing development resulted in a decrease in the levels of B-END 
immunoreactlvlty and a-MSH lmmunoreactlvity in the me- 
dial basal hypothalamus. These results replicate earlier 
radiolmmunoassay studies [9]. Although the B-END 
radlolmmunoassay results were paralleled by a decrease in 
the number of B-END staining cell bodies in the medial 
hypothalamus (arcuate nucleus), cell bodies in the lateral 































































































































































































































































































































HYPOTHALAMUS DORSAL VENTRAL 
CAUDAL CAUDAL 
MEDULLA MEDULLA 
FIG. 4 Beta-endorphm-hke lmmunoreacUvlty (fmol/mg protein) m MSG versus 
control rats Unshaded bar represents sahne control amrnals, shaded bar repre- 
sents MSG animals N=6 per area per condmon fmol/mg protem=femtomoles 
per mdhgrams of protein 
basal hypothalamus were spared and appeared to have m- 
creased in size Although fl-END staining cell bodies in the 
dorsal caudal medulla did not appear to be affected either m 
number or size, there were significant alterations m the 
levels of fl-END immunoreactivity using radlolmmunoassay 
techniques. Of note, fl-END decreased significantly in the 
ventral caudal medulla (VCM) without a concomitant de- 
crease in the dorsal caudal medulla (DCM). 
The lack of a decrease in the levels of fl-END ~m- 
munoreactiwty in the DCM would support the lack of a de- 
crease in cell number in the nucleus tractus solitarlus as 
demonstrated by ~mmunocytochemlstry. If all the material 
w~thin the VCM originated from the DCM, e g ,  nucleus 
tractus sohtarius cell bodies, one would expect that the 
levels of/3-END in the VCM in MSG-treated versus control 
ammals would not decrease, as well. The finding of a sigmfi- 
cant drop m/3-END levels within the VCM suggests that this 
materml originates from an additional site other than the dor- 
sal caudal medulla, such as the arcuate nucleus. With car- 
diovascular and respiratory centers present in VCM areas, 
the hypothalamus could modulate physiological functtomng 
ongmatmg from these areas via these projections. Such "dis- 
tant"  versus "proximal" mnervatlons would allow subtle 
but zmportant modulations 
Whde alteraUons in the levels of a-MSH immunoreactiv- 
~ty in the hypothalamus paralleled those seen w~th fl-END, 
alterations w~thin the caudal medulla were quite different. 
Among MSG-treated animals, a drop in c~-MSH levels com- 
parable to /3-END levels m VCM was not noted. In fact, 
a-MSH levels m the VCM remained unchanged, while 
a-MSH levels m the DCM rose s~gmficantly. One can only 
speculate as to why the alterations in a-MSH levels are dif- 
ferent than those offl-END. Two speculations are: First, the 
distribution of end products of pro-oplomelanocortm 
(POMC)-contammg cells within the dorsal caudal medulla 
(nucleus tractus solitarius) may be regionally specific. This 
same logic may also apply to material originating from out- 
side the dorsal caudal medulla, i.e., the arcuate nucleus or 
possibly other areas of the brain. Thts might explain on an 
anatomical basis why there are differences in levels fol- 





























FIG 5 Apha-MSH-hke lmmunoreactlwty (fmol/mg protein) m MSG versus con- 
trol rats Unshaded bar represents sahne control animals, shaded bar represents 
MSG ammals N=6 per area per condmon fmol/mg protem=femtomoles per 
mdhgrams of protein 
lowing the lesloning of the medial hypothalamus Second, on 
a biochemical basts, the differences may be due to an altera- 
tion in the rates of metabolism, either in production or in 
breakdown. 
The alterations in the levels of c~-MSH are further compli- 
cated by the identification of the alpha-2 group within the lateral 
hypothalamlc area [9,16] These cell bodies have been iden- 
tiffed as being a separate group which contain c~-MSH, yet no 
other POMC-derlved material [20]. Studies have suggested 
that this cell group contains c~-MSH-hke material, not " t rue"  
a-MSH [9] The imphcatlon of this finding is that the a-MSH 
identified within the caudal medulla, both DCM and VCM, 
may represent a combination of POMC-derived a-MSH, 
originating from the dorsal caudal medulla (NTS) and the 
medial basal hypothalamus (arcuate nucleus), and an 
a-MSH-hke materml originating from the alpha-2 cell group 
within the lateral hypothalamus 
Although these explanations might explam steady state 
levels of a-MSH in MSG-lesxoned animals or a differential 
decrease, as was found with/3-END, there remains the ques- 
tion of why a-MSH levels increased in DCM among MSG- 
treated animals versus control animals Any explanation is 
flawed by the lack of knowledge of the site of origin of the 
c~-MSH lmmunoreactlve material, whether "true ~-MSH" 
or "c~-MSH-like." Nevertheless, there are two explanattons 
that can be put forth to explain why post MSG levels ot 
c~-MSH increased" (1) The increase represents the impact of 
the earher lesion, yet does not reflect current need; and (2) 
The increase is reflective of an increased need of a-MSH for 
the current homeostasis of the system. In regard to the first 
explanation, a-MSH has been reported to be atrophic agent in 
the brain [8, 17, 18]. Cells within the dorsal caudal medulla 
(NTS) responsible for the modulation of respiratory and 
cardiovascular functioning, might be influenced by the 
trophlc action(s) of a-MSH during development. Therefore, 
increased levels of a-MSH in the DCM could be explained 
on the basis of the importance of these cells receiving expo- 
sure to c~-MSH during development. Multiple sites, i.e., 
medial and lateral hypothalamus, and medulla, as well as the 
alpha-2 cell group within the lateral hypothalamus, could 
represent a built-in redundancy constituting a fail safe sys- 
tem, which would ensure that c~-MSH or an c~-MSH-11ke 
material reach the nucleus tractus sohtarlus neurons during 
development. Such an alteration resulting from a lesion of 
E F F E C T S  O F  M S G  O N  T H E  C A U D A L  M E D U L L A  695 
o t h e r  p r imary  s~tes m ay  r e m a i n  t h r o u g h o u t  the  life of  the 
animal .  F u r t h e r  s tudies  are o b w o u s l y  n e e d e d  to d e t e r m i n e  
the  a n a t o m y  and  b i o c h e m i s t r y  of  t he se  pep t ldes  and  the i r  
ro les  dur ing  d e v e l o p m e n t  and  m the  physio logica l  funct ion-  
ing of  the  adul t  
In conc lus ion ,  fu ture  s tud ies  o f / 3 - E N D  mater ia l  w~thln 
the  cauda l  medul la ,  especia l ly  s tudies  wh ich  a t t emp t  to 
c h a r a c t e r i z e / 3 - E N D  forms  in this  a rea ,  mus t  t ake  into ac- 
c o u n t  the  signif icant  c o n t r i b u t i o n  of media l  basa l  h y p o t h a -  
lamlc P O M C - c o n t a i n i n g  n e u r o n s  to the levels  o f / 3 - E N D  m 
this  area.  S ince  this  s tudy  was  not  des igned  to d e t e r m i n e  the  
or ig ins  of  the  p ro j ec t i ons  to t he se  a reas  no r  to d i f f e ren t i a t e  
a - M S H  f rom c~-MSH-like ma te r i a l ,  the  h y p o t h e s e s  con-  
c e rn lng  the  a l t e r a t i ons  in the  levels  o f  a - M S H  are  
based  on hml t ed  in format ion  F u r t h e r  s tudies  of  the a - M S H  
cells and  medml  basa l  h y p o t h a l m l c  P O M C - c o n t a i n m g  
n e u r o n s  are needed  to clarify the  role of  t he se  cell g roups  
dur ing  d e v e l o p m e n t ,  l . e ,  do they p roduce  a " t r o p h l c "  
mater ia l  n e c e s s a r y  for  the  d e v e l o p m e n t  of  cauda l  medu l l a  
neu rons ,  and  to d e t e r m i n e  the i r  b~ochemical  compos i t i on  
and  role as phys~ologlcal  modu la to r s  m the  adul t  
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